BioActor develops proprietary health ingredients for use in functional foods, medical nutrition and dietary supplements. Its ingredients target chronic health concerns such as diabetes, osteoporosis and cardiovascular disease that could benefit from preventative dietary measures. The company closed a €2m Series A and intends to use the funds to launch its first product, BONOLIVE, and to finance clinical validation studies for other products in the pipeline. BONOLIVE is clinically proven to stimulate bone-producing cells and will be launched in the USA this year. Investors in the round include ICOS Capital, Nedermaas Ventures and Limburg Ventures, and CEO/founder Hans van der Saag also participated. BioActor operates through alliances with nutrition research institutes (INRA, CSIC, Maastricht University, UCL, Ghent University) and production partnerships with industrial players to shorten commercialization timelines.

Total raised

$3M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2011